Matinas BioPharma
MTNB
55 hedge funds and large institutions have $13.6M invested in Matinas BioPharma in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 6 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
2% more funds holding
Funds holding: 54 → 55 (+1)
0.25% less ownership
Funds ownership: 12.86% → 12.61% (-0.25%)
23% less capital inflows, than outflows
Capital inflows: $954K | Capital outflows: $1.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$159K |
| 2 |
Sargent Investment Group
Bethesda,
Maryland
|
+$118K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$117K |
| 4 |
Global Retirement Partners
San Rafael,
California
|
+$92.3K |
| 5 |
Virtu Financial
New York
|
+$78.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.04M |
| 2 |
Bridgeway Capital Management
Houston,
Texas
|
-$66.9K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$63K |
| 4 |
MONECO Advisors
Fairfield,
Connecticut
|
-$19K |
| 5 |
Global Assets Advisory
Orlando,
Florida
|
-$14K |
MTNB Hedge Fund Activity: Q4 2022 in Review
55 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2022, worth a combined $13.6M — down 24% from $18M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MTNB positions and 6 closed out — a net gain of 2 holders — while 11 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $159K. The largest seller was BlackRock, cutting an estimated $1.04M.
- 55 institutional investors held Matinas BioPharma (MTNB) as of Q4 2022, up from 54 in Q3 2022.
- Funds reported $13.6M of Matinas BioPharma stock for Q4 2022, down 24% quarter-over-quarter.
- 8 funds opened new Matinas BioPharma positions in Q4 2022 and 6 closed out, a net change of +2 holders.
- The largest Matinas BioPharma buyer in Q4 2022 was Millennium Management, an estimated $159K added.
- The largest Matinas BioPharma seller in Q4 2022 was BlackRock, an estimated $1.04M sold.
Based on aggregated 13F filings for Q4 2022.